Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07573579

Dynamic Voltage Mapping to Personalise the Ventricular Tachycardia Substrate

Ventricular tachycardia (VT) is a life-threatening heart rhythm disorder and one of the commonest causes of heart-related sudden death. It often affects people who have had a heart attack or other structural heart damage. VT occurs when abnormal electrical circuits develop within and around scar tissue in the heart.

People at risk are usually offered an implantable cardiac defibrillator (ICD), a device that can detect VT and deliver a lifesaving shock. While effective, these shocks can be sudden, painful and distressing. Medications such as amiodarone can also help, but they are often unsuitable for long-term use due to their potential side effects on the liver, lungs and thyroid gland.

An alternative is catheter ablation. Thin tubes (catheters) are threaded from a blood vessel in the groin to the heart, allowing the cardiologist to identify scar tissue and abnormal electrical circuits, which can be destroyed using heat, freezing or electrical energy.

Although ablation can help many patients, VT can return in up to one in three people after the procedure. This is because it can be difficult to precisely identify the scar and surrounding tissue that sustain the abnormal circuits, making it challenging to know exactly where to apply ablation treatment.

Dynamic Voltage Mapping, is a technique which the investigators believe can more accurately identify scar and the critical bordering tissue during ablation. Initial data collected suggests that the approach accurately predicts the VT circuit and helps guide ablation.

In this study, the investigators wish to recruit 40 participants undergoing VT ablation to determine how effective Dynamic Voltage Mapping is in real-world procedures.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Liverpool Heart and Chest Hospital NHS Foundation Trust

Liverpool, L14 3PE, United Kingdom

Location contact

Justin Chiong, MBChB MSc MRCP

CONTACT

[email protected]

Justin Chiong, MBChB MSc MRCP

SUB_INVESTIGATOR

Vishal Luther, MRCP PhD ECES ECDS

CONTACT

[email protected]

0151 600 1251

Vishal Luther, MRCP PhD ECES ECDS

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Scheduled for clinically indicated VT ablation (due to sustained VT episodes or ICD therapies).
  • Willing and able to give informed consent for participation in the trial
  • Male or female aged between 18-85
  • Ischaemic and non-ischaemic cardiomyopathy
  • ICD insitu

Exclusion criteria

  • Unable or unwilling to consent
  • NYHA Class IV (end stage heart failure)
  • Metastatic cancer
  • End stage renal disease
  • Pregnant or breast feeding
  • Severe frailty

Treatment and study plan

Dynamic Voltage Mapping

Procedure

Dynamic Voltage Mapping uses electrical information collected from catheters positioned within the heart to create an individualised map of the heart, which the investigators hypothesise will better identify scar and surrounding tissue responsible for ventricular tachycardia.

Other names: DVM, Dynamic Voltage Map

Standard of Care Ablation

Procedure

Standard catheter ablation of ventricular tachycardia, guided by operator preference

Other names: Catheter ablation

Primary outcomes

  1. Study Feasibility

    Time frame: From enrolment to end of follow up (1 year after procedure)

    • Proportion of screened patients who were eligible, approached, consented and recruited
    • Attrition rate: calculated as the total number of recruited patients who withdrew from the study or were lost to follow up
    • Adherence: calculated as the proportion of recruited participants who were able to fully follow the study protocol in both DVM and standard of care arms during their VT ablation procedure.

Secondary outcomes

  1. Procedural Time

    Time frame: From start of procedure to end (skin-to-skin)

    Measured in minutes

  2. Ablation time/number of lesions

    Time frame: From start of procedure to end (skin-to-skin)

    Measured by number of ablation lesions applied

  3. Acute VT non-inducibility

    Time frame: From start of procedure to end (skin-to-skin)

    Ability to induce clinical VT at the end of the procedure

  4. VT recurrence Rate

    Time frame: From end of procedure to end of follow up (12 months)

    Number of sustained VT episodes/ICD shocks/therapies following procedure, recorded by implanted cardiac device

Sponsors and collaborators

Lead sponsor

Liverpool Heart and Chest Hospital NHS Foundation Trust

Other

Registry information

Acronym: DYNAMITE-VT

Important dates

Study start
2026
Primary completion
2029
Study completion
2029
First posted
May 7, 2026
Registry last updated
May 7, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.